The key is rapid marketing, says Irish medtech industry
This article was originally published in Clinica
The success of Ireland's medical technology industry lies in its ability to market products quickly, on the back of "good regulation". So said Helen Ryan, chairperson of the Irish Medical Devices Association (IMDA) today, at the launch of the Global Access forum (Dromoland, County Clare, November 5-6).
You may also be interested in...
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
The US FDA has overhauled its ‘Purple Book’ to make it a searchable database of biologics information. The agency is also seeking input on next steps.
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.